机构:[1]Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China[2]Sichuan Coll Tradit Chinese Med, Res & Expt Ctr, Mianyang, Peoples R China[3]Cell Therapy & Cell Drugs Luzhou Key Lab, Luzhou, Peoples R China[4]South Sichuan Inst Translat Med, Luzhou, Peoples R China[5]Southern Med Univ, Shenzhen Hosp, Dept Gastroenterol, Shenzhen, Guangdong, Peoples R China[6]Gulin Tradit Chinese Med Hosp, Luzhou, Peoples R China
The gut microbiota, a complex microbial ecosystem closely connected to the liver via the portal vein, has emerged as a critical regulator of liver health and disease. Numerous studies have underscored its role in the onset and progression of liver disorders, including alcoholic liver disease, metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). This review provides a comprehensive overview of current insights into the influence of the gut microbiota on HCC progression, particularly its effects on immune cells within the HCC tumor microenvironment (TME). Furthermore, we explore the potential of gut microbiota-targeted interventions, such as antibiotics, probiotics, prebiotics, and fecal microbiota transplantation (FMT), to modulate the immune response and improve outcomes of immunotherapy in HCC. By synthesizing insights from recent studies, this review aims to highlight microbiota-based strategies that may enhance immunotherapy outcomes, advancing personalized approaches in HCC treatment.
基金:
National Natural Science Foundation of China [82172962]; Sichuan Natural Science Foundation Project [2023NSFSC0717]; SCU-Luzhou Platform Construction of Scientific and Technological Innovation [2022CDLZ-20]
第一作者机构:[1]Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Southwest Med Univ, Sch Pharm, Dept Pharmacol, Lab Mol Pharmacol, Luzhou, Peoples R China[2]Sichuan Coll Tradit Chinese Med, Res & Expt Ctr, Mianyang, Peoples R China[3]Cell Therapy & Cell Drugs Luzhou Key Lab, Luzhou, Peoples R China[4]South Sichuan Inst Translat Med, Luzhou, Peoples R China[6]Gulin Tradit Chinese Med Hosp, Luzhou, Peoples R China
推荐引用方式(GB/T 7714):
Ren Siqi,Zhang Yinping,Wang Xingyue,et al.Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma[J].FRONTIERS IN IMMUNOLOGY.2025,16:doi:10.3389/fimmu.2025.1526967.
APA:
Ren, Siqi,Zhang, Yinping,Wang, Xingyue,Su, Jiahong,Wang, Xiang...&Xiao, Zhangang.(2025).Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma.FRONTIERS IN IMMUNOLOGY,16,
MLA:
Ren, Siqi,et al."Emerging insights into the gut microbiota as a key regulator of immunity and response to immunotherapy in hepatocellular carcinoma".FRONTIERS IN IMMUNOLOGY 16.(2025)